共 50 条
- [41] Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label studyJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 174 - 175Paller, A.Becker, E.de Lucas, R.Paris, M.Zhang, W.Zhang, Z.Barcellona, C.Maes, P.Fiorillo, L.
- [42] A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)BLOOD, 2020, 136Zhang, FengkuiPeng, GuangxinHe, GuangshengChang, HongGao, SujunLiu, XinjianChen, TongLi, PeiHan, BingMiao, MiaoGe, ZhengGe, XiaoyanLi, FeiLi, YingmeiWang, ShunqingWang, YiShen, YaqiTai, YanfeiZhang, TaoZhu, BoZou, Jianjun
- [43] An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Janku, FilipHamilton, Erika PaigeChu, ChristinaRichardson, Debra L.Arend, Rebecca ChristianKuida, KeisukeAchour, HarounRuiz-Soto, RodrigoHays, John L.
- [44] An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Middleton, Mark R.Sacco, Joseph J.Merchan, Jaime R.Curti, Brendan D.Vanderwalde, Ari M.Olsson-Brown, Anna ClaireAroldi, FrancescaFotiadis, NicosBaum, ScottCoffin, Robert S.Kaufman, HowardHarrington, Kevin J.
- [45] Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanomaMELANOMA RESEARCH, 2010, 20 (06) : 507 - 510Homsi, JadeBedikian, Agop Y.Papadopoulos, Nicholas E.Kim, Kevin B.Hwu, Wen-JenMahoney, Sandy L.Hwu, Patrick
- [46] EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDYHAEMATOLOGICA, 2021, 106 (10) : 2 - 2Vannucchi, A. M.DeAngelo, D. J.Reiter, A.Radia, D.Deininger, M. W.George, T. I.Panse, J.Jentzsch, M.Alvarez-Twose, I.Mital, A.Hermine, O.Dybedal, I.Hexner, E. O.Hicks, L. K.Span, L.Mesa, R.Bose, P.Pettit, K. M.Heaney, M. L.Oh, S.Sen, J.Lin, H-M.Mar, B. G.Gotlib, J.
- [47] Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Janku, FilipHamilton, Erika P.Mathews, Cara AmandaChu, ChristinaDiamond, Jennifer RobinsonHays, John L.Arend, Rebecca ChristianCristofanilli, MassimoJewell, AndreaReichmann, WilliamKuida, KeisukeAchour, HarounRuiz-Soto, RodrigoRichardson, Debra L.
- [48] An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinomaANNALS OF ONCOLOGY, 2023, 34 : S34 - S35Elez, E.Shepard, D.Smolenschi, C.Bekaii-Saab, T.Jac, J.
- [49] Preliminary safety, pharmacokinetics, and efficacy results from an open-label, multicenter, Phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Li, JianGong, JifangWang, XichengLi, JieLi, YanQi, ChangsongShen, LinRen, WenxiaoZhao, WanqiWang, YedongHu, JinRen, ChunliSong, WenjieYang, Jianxin
- [50] Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Passamonti, FrancescoForan, James M.Tandra, AnandDe Stefano, ValerioFox, Maria LauraMattour, Ahmad HatemMcMullin, Mary FrancesPerkins, AndrewRodriguez-Macias, GabrielaSibai, HassanQin, Qin Q.Potluri, JalajaHow, Jonathan B.